SCM
IPSC icon

Sterling Capital Management’s Century Therapeutics IPSC Stock Holding History

Sterling Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-807
Closed -$384 – 3323
2025
Q1 		$384 Sell
807
-782
-49% -$588 ﹤0.01% 3007
2024
Q4 		$1.6K Buy
1,589
+1,443
+988% +$1.96K ﹤0.01% 2837
2024
Q3 		$250 Buy
+146
New +$286 ﹤0.01% 3077

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sterling Capital Management's IPSC Position: Q2 2025 in Review

Sterling Capital Management sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 807 shares — an estimated $384 sold.

Sterling Capital Management first reported a position in IPSC in Q3 2024 and held it in 3 quarters. The position peaked at $1.6K in Q4 2024. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • Sterling Capital Management reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 807 Century Therapeutics shares in Q2 2025, an estimated $384.
  • Sterling Capital Management first reported a position in Century Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Century Therapeutics position peaked at $1.6K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.